Lipitor-Zetia combo-pill planned

Share this article:
Merck/Schering-Plough says it plans to sell its Zetia cholesterol inhibitor in combination with a generic version of Pfizer’s Lipitor. The pill could be available once US and international patents expire for Lipitor (atorvastatin), which could be as early as 2010. Lipitor had 2006 global sales of about $12.9 billion, according to Pfizer. The MSP joint venture already markets Zetia in a combination pill with Zocor. That drug, Vytorin, had 2006 global sales of $1.96 billion. Vytorin uses a dual approach to the treatment of high cholesterol, blocking cholesterol absorption in the small intestine (Zetia) and lowering production in the liver (Zocor). Considering Lipitor is more widely prescribed and studies show it is more effective than Zocor, the planned pill could prove even more successful, notes Bloomberg. The companies said they tested a Zetia-Lipitor combination and found that co-administration of the drugs lowered LDL or “bad” cholesterol by an average of 53% to 61%, compared to average LDL cholesterol reductions of 37% to 54% with atorvastatin alone.
Share this article:

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?